ZEPP // Zepp Health Corporation each representing sixteen (Class A)
FA <GO> NYSE RQD COCKPIT → CIK 0001720446 ↗ Technology • Computer Manufacturing
$2.25 ▼ -0.09
(-3.85%)
MKT CAP: $33.0M • VOL: 68.7K
52W L $2 52W H $42
ZEPP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $258.9M | $182.6M | $352.9M |
| YoY Revenue Growth % | +41.8% | -48.3% | — |
| Gross Profit | $99.2M | $70.2M | — |
| Gross Margin % | 38.3% | 38.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$29.2M | -$47.3M | -$30.4M |
| Operating Margin % | -11.3% | -25.9% | -8.6% |
| Net Income (GAAP) | -$40.1M | -$75.7M | -$31.0M |
| EBITDA (Normalized) | -$28.8M | -$46.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.7M | -$24.4M | $42.6M |
| Capital Expenditures (CapEx) | $516.0K | $1.4M | — |
| Free Cash Flow (FCF) | -$26.2M | -$25.8M | $42.6M |
| FCF Margin % | -10.1% | -14.1% | 12.1% |
| Return on Invested Capital (ROIC %) | -14.7% | -23.3% | — |
| Cash & Short-Term Equivalents | $57.0M | $91.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $214.5M | $251.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZEPP.